The 4 analysts offering 12-month price forecasts for Lineage Cell Therapeutics Inc have a median target of 4.00, with a high estimate of 7.00 and a low estimate of 3.00. The median estimate represents a +284.62% increase from the last price of 1.04.
The current consensus among 5 polled investment analysts is to Buy stock in Lineage Cell Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.05
Reporting Date Mar 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.